Glycopeptides

Key Points

• Glycopeptides inhibit bacterial cell-wall synthesis and are used for serious gram-positive infections.
• Vancomycin is the core prototype and is commonly used in MRSA treatment pathways.
• IV vancomycin is used for systemic infection; oral (or protocol-based rectal instillation) vancomycin is used for localized C. diff colitis pathways.
• Vancomycin requires trough-guided dosing and renal-dose adjustment to reduce nephrotoxicity and ototoxicity risk.
• Rapid IV infusion can cause vancomycin flushing syndrome with rash, pruritus, and hypotension.
• Culture collection before first dose and full-course adherence remain core nursing priorities.

Class Overview

Glycopeptides are antibacterial agents with primary activity against gram-positive organisms. In bedside practice, vancomycin is the most common class representative and is frequently reserved for severe infection when other options are ineffective, contraindicated, or resistance patterns require glycopeptide coverage.

Because oral absorption is poor, route selection is a high-priority safety decision: IV route for systemic infection and oral route for intestinal C. diff treatment pathways.

Prototype Highlights

Vancomycin

• Primary indications: Serious gram-positive infection (including MRSA) and C. diff treatment pathways.
• Route rules:
  • IV for systemic infection.
  • Oral (or protocol-based rectal instillation) for C. diff colitis.
• Monitoring priorities:
  • Obtain culture before first dose when possible.
  • Monitor trough levels for dose targeting.
  • Adjust dose for renal impairment.
• Infusion requirement: Administer diluted IV doses over at least 60 minutes to reduce rapid-infusion reactions.
• Adverse-effect profile: Nephrotoxicity, ototoxicity, and delayed C. diff-associated diarrhea risk.

Vancomycin Flushing Syndrome

Vancomycin flushing syndrome is a histamine-mediated infusion reaction that can occur when IV vancomycin is infused too rapidly.

Common findings include maculopapular erythematous rash over face/neck/trunk/extremities, pruritus, and hypotension.

Rapid-Infusion Reaction Response

If vancomycin flushing syndrome occurs: stop infusion, notify the provider, monitor blood pressure closely, and prepare ordered treatment (for example diphenhydramine, IV fluids, and vasopressor support when indicated). Restart only after symptoms improve and at a slower infusion rate.

Nursing Considerations

• Verify route appropriateness for the infection site before administration.
• Confirm trough-sampling schedule and do not administer scheduled IV doses before required trough collection is completed.
• Monitor renal function (BUN/creatinine/urine output trends) and hearing/balance symptoms (tinnitus, hearing loss, vertigo).
• Reinforce full-course adherence and prompt follow-up when symptoms do not improve.
• Teach patients to report rash, pruritus, dizziness, hypotension symptoms, tinnitus, and hearing changes promptly.
• Continue monitoring for late antibiotic-associated diarrhea because C. diff can present after the acute treatment window.

Related Concepts

• antibiotics - Antibacterial class framework and stewardship principles.
• clostridioides-difficile-infection - C. diff-focused route strategy and isolation workflow.
• ototoxic-medications - Hearing and vestibular toxicity assessment priorities.
• medication-onset-peak-duration - Peak/trough timing and dose-adjustment workflow.
• antimicrobial-stewardship - Resistance-aware antibiotic selection and treatment completion.

Self-Check

1. Why is oral vancomycin not interchangeable with IV vancomycin for systemic infection treatment?
2. What is the safest nursing response when a vancomycin dose is due but the required trough has not been collected?
3. Which signs suggest vancomycin flushing syndrome, and what immediate actions are required?